Physician profile
Michael B Boyd
NPI 1487839270
$4,646.85
in general payments reported to CMS, 2019-2025
30 companies · $50.75 in 2025
The $50.75 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $1,074 · 2021: $1,220 · 2022: $1,070 · 2025: $50.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,064.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $751.13 | 2019-2022 | |
| Mylan Specialty L.P. | $380.40 | 2019-2022 | |
| United Therapeutics Corporation | $325.33 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $277.82 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.28 | 2019-2022 | |
| Philips North America LLC | $177.28 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $171.34 | 2019 | |
| Mallinckrodt Hospital Products INC. | $164.23 | 2020-2022 | |
| Genzyme Corporation | $142.59 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.83 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $103.81 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $96.14 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $75.53 | 2019-2022 | |
| Allergan, INC. | $72.06 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $62.89 | 2019-2022 | |
| Electromed, INC. | $61.86 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $51.65 | 2022 | |
| Novo Nordisk INC | $50.75 | 2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $49.01 | 2019-2020 | |
| Pfizer INC. | $47.19 | 2020-2021 | |
| Csl Behring | $41.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.55 | 2019-2022 | |
| Genentech USA, INC. | $27.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $24.98 | 2021 | |
| Biogen, INC. | $23.00 | 2020 | |
| Resmed Corp | $22.20 | 2019-2020 | |
| Insmed, INC. | $16.14 | 2019 | |
| Abbvie INC. | $14.35 | 2022 | |
| Amgen INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.